Chemical Probes logo
Brivanib | Brivanib : ATP competitive inhibitor of KDR
RATINGS:
Cellular Use: (1 reviews)

In Model Organisms: (1 reviews)
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download

Probe Summary

More...

Targets Biochemical/Biophysical Potency Cellular Potency
KDR
  • IC50:26 nM
  • Ki:25 nM
  • IC50:40 nM
  • IC50:276 nM
1 µM
up to 10 uM

Selectivity

In Vitro Selectivity Assessment

Potency: IC50 - FLK1 89 nM, FGFR1 148 nM

Selectivity Assessment Description:
Kinase Selectivity IC50 (nM): VEGFR-1 380, FGFR-1 148, PDGFR-β >6000, EGFR >1900, LCK >2 ...

Potency
Cellular
In Vitro

KDR

Mode of Action: ATP competitive

Structure-Activity-Relationship data available? Yes

DOI Reference: 10.1021/jm051106d

In Vivo Validations

Mouse, Rat
Dose: 10, 60, 90 Mg/Kg
Route of delivery: Intravenous, Oral
Plasma half life: 2.7 (IV), 3.6 (PO) h
Systemic clearance: 9.3 (IV) mL/min/kg

DOI Reference: 10.1021/jm051106d

Orthogonal Probes def

CABOZANTINIB
Tivozanib
GOLVATINIB TARTRATE

Chemical Information

Molecular Formula C19H19FN4O3
SMILEs Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
InChI InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
Molecular weight 370.14 Da
AlogP 3.518440000000002
HBond acceptors 7
HBond donors 2
Atoms 46

Vendors

Note: This is not an exhaustive list and does not indicate endorsement by the Portal.

Expert Reviews

by SERP
(on 19 Oct 2025)
Cellular Use Rating
In Model Organisms
Brivanib (BMS-540215) is a potent ATP-competitive inhibitor of KDR (VEGFR2) kinase. Due to limited selectivity data (only KDR plus seven additional kinases were tested), additional data would be necessary...
If you would like to explore AI-generated evaluations, you may wish to visit the page for this compound on our collaborator website
Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria